OMEROS CORP Income Taxes Receivable, Current
OMEROS CORP (OMER) had Income Taxes Receivable, Current of $2.13 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes › and Others › Nontrade Receivables, Current
us-gaap:IncomeTaxesReceivable · last filed 2023-05-09
- 2023-03-31: Income Taxes Receivable, Current $2.13M.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2023-03-31 | $2.13M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |